JWJun Wang

Jun Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jun Wang has a total of 421 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cross-species spatial profiling links progranulin to an immune suppressive niche in brain metastasis

    by Nicole M. Eskow, Kylie Prutisto-Chang, Maria A. Gomez-Munoz, Minkyung Kang, Irineu Illa Bochaca, Milad Ibrahim, Sorin A.A. Shadaloey, Amanda Flores Yanke, Luiz Henrique Geraldo, Giuseppe Barisano, et al.

    Immune checkpoint inhibitors (ICI) have revolutionized the treatment of brain metastasis (BM), demonstrating intracranial response rates and durability not previously seen with other therapies. However, approximately 50% of patients do not respond to ICI, and the brain-specific interactions that shape anti-tumor immunity remain poorly understood. We profiled five syngeneic BM models using spatial transcriptomics, identifying myeloid-rich niches enriched for interferon-responsive and disease-associated microglia (DAM)-like programs. Ligand-receptor colocalization analyses identified progranulin (PGRN) as a candidate mediator of these niches. Host- or tumor-cell Grn loss reduced BM burden, and Grn -deficient macrophages exhibited altered metabolic programs and tumor-cell engulfment in vitro. Across independent human BM datasets, GRN expression was associated with conserved lysosomal and DAM-like myeloid programs, and GRN -high myeloid regions colocalized with immunosuppressive signatures and dysfunctional CD8+ T cell states. These cross-species findings identify PGRN as a candidate mediator of the BM immune niche and support further investigation of its therapeutic relevance. Highlights: A multi-model spatial atlas resolves myeloid niches in both preclinical models of brain metastases and human patient tissues Host- and tumor-cell progranulin support brain metastatic growth Progranulin associates with lysosomal function and disease-associated myeloid states in brain metastasis Human progranulin-rich myeloid niches colocalize with dysfunctional cytotoxic T cells in brain metastasis Graphical

  • The liver-secreted protein FGL1 restrains a subset of innate-like B cell responses via the receptor TACI

    by Tina Tianjiao Su, Jianwei He, Yuge Wang, Jiaoyan Huang, Baozhu Huang, Ala Nassar, Laure Willen, Mahya Eslami, Chunxiang Wu, Meiyi Huang, et al.

  • Open Access

    PRECISE-seq reveals disease-relevant TCR repertoires with phenotypic plasticity

    by Shibo Liu, Guanghao Liang, Yayun Yang, Yanyang Shi, Lihui Dong, Yue Zhao, Boyuan Mei, Jun Wang, Feng Lin, Yilin Li, et al.

    Linking T cell phenotypes with antigen specificity and functional avidity is critical for understanding in vivo immune responses in infection and cancer. Here, we develop PRECISE-seq, a method that integrates multi-omics T cell analysis with contact-dependent proximity labeling for rapid screening of disease-relevant T cell repertoires, and for linking the relative TCR avidity with T cell phenotypes at single-cell resolution. PRECISE-seq accurately retrieves CMV-specific clonotypes from human peripheral blood and quantitatively measures functional avidity in physiological contexts. We find that high-potency CMV-specific T cells preferentially acquire an exhausted phenotype. In tumors, polyclonal tumor-reactive CD8+ T cells predominantly differentiate into a protumor Ly49+ regulatory state (TLy49), characterized by inhibitory killer cell lectin-like receptor expression and originating from effector memory T cells along a trajectory distinct from exhaustion. Notably, PD-1 blockade reduces TLy49 formation and promotes effector revival, which correlates with responsiveness to immunotherapy. Together, PRECISE-seq enables high-resolution mapping of TCR potency and T cell phenotype, revealing a regulatory axis shaping T cell fate in tumors.


  • Open Access

    Lypd6b depletion promotes CD8+ T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer

    by Ting Liu, Fanxin Zeng, Zuyin Li, Leirong Cheng, Xuanxuan Yan, Haiqiang Chen, Qin Liu, Xue Li, Zhao Li, Jiaheng Yao, et al.

    Lymphocyte antigen-plasminogen activator urokinase receptor domain-containing protein 6B (Lypd6b) is a newly identified molecule associated with neuromodulation. However, the role of Lypd6b in regulating the tumor microenvironment and its impact on CD8+ T cell-mediated antitumor immunity remain unknown. Here, we observe that Lypd6b expression is increased significantly in colorectal cancer (CRC) tumor tissues compared to normal tissues. Lypd6b is mainly expressed in CD8+ T cells in tumor tissues. Lypd6b knockout (Lypd6b−/−) mice are resistant to AOM/DSS-induced tumorigenesis. Furthermore, global deficiency or CD8+ cell deficiency of Lypd6b inhibits MC38 or CMT-93 tumor growth and promotes the infiltration of CD8+ T cells. Mechanistically, Lypd6b deficiency promotes activation and function of CD8+ T cells in anti-tumor response with increased glycolysis and reduced oxidative phosphorylation in a PI3K/mTOR/LDHA pathway-dependent manner. Notably, Lypd6b deficient CD8+ T cells have a more potent antitumor effect when combined with anti-PD1 antibody. Thus, Lypd6b as a negative regulator for T cell immunity promotes CRC development, providing a molecular target with therapeutic potential in CRC.


  • Open Access

    T lymphocyte–specific deletion of SHP1 and SHP2 promotes activation-induced cell death of CD4 + T cells and impairs antitumor response

    by Connor J. R. Foster, Jasper Du, Oscar Pundel, Mitchell J. Geer, Ryan C. Ripert, Jia Liu, Taylor A. Heim, Kiyomi Y. Araki, Amanda W. Lund, Jun Wang, et al.

    SHP1 (PTPN6) and SHP2 (PTPN11) are closely related protein-tyrosine phosphatases (PTPs), which are autoinhibited until their SH2 domains bind paired tyrosine-phosphorylated immunoreceptor tyrosine-based inhibitory/switch motifs (ITIMs/ITSMs). These PTPs bind overlapping sets of ITIM/ITSM-bearing proteins, suggesting that they might have some redundant functions. By studying T cell–specific single and double knockout mice, we found that SHP1 and SHP2 redundantly restrain naïve T cell differentiation to effector and central memory phenotypes, with SHP1 playing the dominant role. Surprisingly, loss of SHP2 alone in T cells enhanced the antitumor effects of anti-PD-1 antibodies, whereas there was no effect of SHP1 deletion. Also unexpectedly, the absence of both PTPs resulted in poorer tumor control and failure to respond to Programmed Cell Death Protein 1 (PD-1) blockade, associated with reduced frequency and activation of T cells and dendritic cells. Mechanistic studies revealed that CD4 + , but not CD8 + , T cells lacking SHP1 and SHP2 show increased activation-induced cell death upon anti-CD3/CD28 stimulation. Adoptive transfer of antigen-specific CD4 + T cells restored normal levels of tumor control in mice lacking both PTPs. Together, our results demonstrate that SHP1 or SHP2 is required to prevent activation-induced cell death of CD4 + T cells and is critical for tumor immunity, raising the possibility that inhibition of SHP2 might augment the therapeutic efficacy of PD-1-based immune therapy.


  • Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity

    by Jasper Du, Hui Chen, Jia You, Wei Hu, Jia Liu, Qiao Lu, Yong Zhang, Jie Gao, Meng-Ju Lin, Connor James Ryan Foster, et al.


  • Exploring new frontiers in LAG-3 biology and therapeutics

    by Jun Wang, Christian Klein, Jennifer R. Cochran, Jonathan Sockolosky, Shaun M. Lippow


  • Open Access

    T Lymphocyte-Specific Deletion of SHP1 and SHP2 Promotes Activation-Induced Cell Death of CD4+ T Cells and Impairs Antitumor Response

    by Connor J.R. Foster, Jasper Du, Oscar Pundel, Mitchell J. Geer, Ryan C. Ripert, Jia Liu, Taylor A. Heim, Kiyomi Y. Araki, Amanda W. Lund, Jun Wang, et al.

    SHP1 (PTPN6) and SHP2 (PTPN11) are closely related protein-tyrosine phosphatases (PTPs), which are autoinhibited until their SH2 domains bind paired tyrosine-phosphorylated immunoreceptor tyrosine-based inhibitory/switch motifs (ITIMs/ITSMs). These PTPs bind overlapping sets of ITIM/ITSM-bearing proteins, suggesting that they might have some redundant functions. By studying T cell-specific single and double knockout mice, we found that SHP1 and SHP2 redundantly restrain naïve T cell differentiation to effector and central memory phenotypes, with SHP1 playing the dominant role. Surprisingly, loss of SHP2 alone in T cells enhanced the antitumor effects of anti-PD-1 antibodies, whereas there was no effect of SHP1 deletion. Also unexpectedly, the absence of both PTPs resulted in poorer tumor control and failure to respond to PD-1 blockade, associated with reduced frequency and activation of T cells and dendritic cells. Mechanistic studies revealed that CD4+, but not CD8+ T cells lacking SHP1 and SHP2 show increased activation-induced cell death upon anti-CD3/CD28 stimulation. Adoptive transfer of antigen-specific CD4+ T cells restored normal levels of tumor control in mice lacking both PTPs. Together, our results demonstrate that SHP1 or SHP2 is required to prevent activation-induced cell death of CD4+ T cells and is critical for tumor immunity, raising the possibility that inhibition of SHP2 might augment the therapeutic efficacy of PD-1-based immune therapy. SIGNIFICANCE STATEMENT: SHP1 and SHP2 are related protein tyrosine phosphatases that associate with several of the same ITIM/ITSM-containing receptors or T cell receptor (TCR) signaling molecules. The individual roles of SHP1 and SHP2 in T cells have been reported previously, but potentially redundant functions are less well understood. Here we uncover an essential function in CD4+ T cells that is manifest only in the absence of both enzymes and is critical for the control of tumors.


  • Open Access

    Lypd6b promotes colon tumorigenesis by inhibiting CD8+ T cell-mediated anti-tumor immunity through metabolic reprogramming

    by Jinhua Zhang, Ting Liu, Fanxin Zeng, Zuyin Li, Xuanxuan Yan, Leirong Cheng, Haiqiang Chen, Qin Liu, Xue Li, Zhao Li, et al.

    Lymphocyte antigen-plasminogen activator urokinase receptor domain-containing protein 6B (Lypd6b) is a newly discovered molecule associated with neuromodulation. However, the specific role of Lypd6b in colorectal cancer (CRC) remains unknown. Here, Lypd6b knockout (Lypd6b−/−) mice were generated and an azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colitis-associated colorectal cancer (CAC) model was established. Lypd6b−/− mice are sensitive to DSS-induced colitis but were resistant to AOM/DSS-induced tumorigenesis as evidenced by the decrease in the number and sizes of tumors. Lypd6b deficiency also inhibited MC38 tumor growth. Mechanistically, Lypd6b deficiency promoted activation and function of CD8+ T cells in anti-tumor response with increased glycolysis and reduced oxidative phosphorylation (OXPHOS) in a PI3K/mTOR/LDHA pathway-dependent manner. Furthermore, LYPD6B expression is significantly upregulated in CRC. CRC patients with low Lypd6b expression exhibited increased CD8+ T cell infiltration and altered glycolysis. Thus, Lypd6b as a negative regulator for T cell immunity promotes CRC development, providing a molecular target with therapeutic potential in CRC.

  • Open Access

    Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function

    by John L. Silberstein, Jasper Du, Kun-Wei Chan, Jessica A. Frank, Irimpan I. Mathews, Yong Bin Kim, Jia You, Qiao Lu, Jia Liu, Elliot A. Philips, et al.

    Lymphocyte activation gene-3 (LAG-3) is an inhibitory receptor expressed on activated T cells and an emerging immunotherapy target. Domain 1 (D1) of LAG-3, which has been purported to directly interact with major histocompatibility complex class II (MHCII) and fibrinogen-like protein 1 (FGL1), has been the major focus for the development of therapeutic antibodies that inhibit LAG-3 receptor-ligand interactions and restore T cell function. Here, we present a high-resolution structure of glycosylated mouse LAG-3 ectodomain, identifying that cis-homodimerization, mediated through a network of hydrophobic residues within domain 2 (D2), is critically required for LAG-3 function. Additionally, we found a previously unidentified key protein-glycan interaction in the dimer interface that affects the spatial orientation of the neighboring D1 domain. Mutation of LAG-3 D2 residues reduced dimer formation, dramatically abolished LAG-3 binding to both MHCII and FGL1 ligands, and consequentially inhibited the role of LAG-3 in suppressing T cell responses. Intriguingly, we showed that antibodies directed against D1, D2, and D3 domains are all capable of blocking LAG-3 dimer formation and MHCII and FGL-1 ligand binding, suggesting a potential allosteric model of LAG-3 function tightly regulated by dimerization. Furthermore, our work reveals unique epitopes, in addition to D1, that can be targeted for immunotherapy of cancer and other human diseases.